Get started
Author

Shanti Amé

Observed names: Amé, S., S. Ame, Shanti Ame, Shanti Natarjan Amé
ORCID: 0009-0009-6199-281X
Observed ORCID: 0009-0009-6199-281X
OpenAlex ID: A5103277592
Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies
2014 · Philippe Barthélémy, Irène Asmane-De la Porte, et al. · Oncology · 39
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
2018 · Sophie Park, Olivier Kosmider, et al. · Haematologica · 24
PDF
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis
2016 · Emmanuel Gyan, Valérie Andrieu, et al. · British Journal of Haematology · 19
PDF
A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial
2018 · Lionel Ades, Agnès Guerci, et al. · Blood · 13
Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study
2016 · Christian Rose, Olivier Fitoussi, et al. · Blood · 7
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
2023 · Shanti Amé, Fiorenza Barraco, et al. · eJHaem · 5
PDF
Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study
2024 · Marie Gérardin, Morgane Rousselet, et al. · Orphanet Journal of Rare Diseases · 3
PDF
A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)
2021 · Arsène Mékinian, Lin-Pierre Zhao, et al. · Blood · 3
Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
2022 · Yannick LE Bris, Jean Galtier, et al. · Blood · 1
Adherence and patients’ attitude toward oral anticancer drugs: A prospective series of 226 patients focusing onto targeted therapies.
2013 · Philippe Barthelemy, Louis-Marie Dourthe, et al. · Journal of Clinical Oncology · 1
Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study
2025 · Colin Vercueil, Romain Varnier, et al. · Supportive Care in Cancer
PDF
2054P Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
2023 · C. Vercueil, R. Varnier, et al. · Annals of Oncology
PDF
Maladies de l’hémoglobine et thromboses artérielles/veineuses
2022 · Shanti Amé · JMV-Journal de Médecine Vasculaire
Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes
2018 · Sophie Park, Olivier Kosmider, et al. · SSRN Electronic Journal
Germline Mutations Occurring Outside the Negatively Charged Amino Acid Stretches of the Exon 9 of Calr : A Predisposition to Hematological Malignancies?
2017 · Laurent Miguet, Carine Gervais, et al. · Blood
303 Clinical and Morphological Characteristics of 23 Patients With Myelodysplasic Syndrome Associated With Isolated Del(5q)
2015 · A. Eischen, A. Ittel, et al. · Leukemia Research
213 Azacitidine (aza) in Higher Risk Mds Patients With Chromosome 7 Abnormalities (abn 7): Results of a Retrospective Study From the Gfm and Gesmd Registries
2015 · M. Díez Campelo, J.I. Lorenzo, et al. · Leukemia Research
Supplementary Material for: Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies
2014 · Barthélémy, P., Asmane-De La Porte, I., et al. · Figshare
99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients
2011 · S. Park, R. Sapena, et al. · Leukemia Research
Apport de la radiothérapie conformationnelle tridimensionnelle avec modulation d’intensité (RCMI) dans la maladie de Hodgkin: étude dosimétrique comparant une tomothérapie et une radiothérapie conformationnelle tridimensionnelle
2010 · D. Antoni, P. Meyer, et al. · Cancer/Radiothérapie
Works count: 20
Citation count: 115
H-index: 5
I10-index: 4
Year
Topic
Type